SEC Form 4 · accession 0001179110-17-001602
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher P Leamon
Officer — Vice President of Research
Period of report
Feb 2, 2017
Accepted (ET)
Feb 3, 2017 · 3:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 2, 2017 | A | 17,500 | $0.00 | A | 84,483 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.16 | Feb 2, 2017 | A | 35,000 | D | — | Feb 2, 2027 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1Represents restricted stock units that will vest and be paid 1/4 annually over a period of 4 years beginning on February 2, 2018, in the form of one share of common stock for each restricted stock unit.
- F2Shares subject to the option vest 1/4 annually over a period of 4 years beginning on February 2, 2018.